Is there still hope for the prophylactic hepatitis C vaccine? A review of different approaches

P Rzymski, AT Jibril, L Rahmah… - Journal of Medical …, 2024 - Wiley Online Library
Despite remarkable progress in the treatment of hepatitis C virus (HCV) infection, it remains
a significant global health burden, necessitating the development of an effective prophylactic …

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

M Sallam, R Khalil - Microorganisms, 2024 - mdpi.com
Hepatitis C virus (HCV) remains a significant global health challenge. Approximately 50
million people were living with chronic hepatitis C based on the World Health Organization …

[HTML][HTML] Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study

P Ryan, J Valencia, G Cuevas… - …, 2024 - eurosurveillance.org
Background People who use drugs (PWUD) are a key target population to reduce the
burden of hepatitis C virus (HCV) infection. Aim To assess risk factors and temporal trends of …

[HTML][HTML] Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

C Thomadakis, I Gountas, E Duffell… - The Lancet Regional …, 2024 - thelancet.com
Background Epidemiological data are crucial to monitoring progress towards the 2030
Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of …

Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data …

R Sacks-Davis, DK van Santen, A Boyd, J Young… - The Lancet …, 2024 - thelancet.com
Background Reinfection after successful treatment with direct-acting antivirals is
hypothesised to undermine efforts to eliminate hepatitis C virus (HCV) infection among …

Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective …

CJ Isfordink, A Boyd, R Sacks-Davis… - The Lancet Public …, 2023 - thelancet.com
Background Individuals with HIV and hepatitis C virus (HCV) who remain untreated with
direct-acting antivirals can contribute to HCV transmission and HCV-related mortality. We …

Medicaid Expansion and Restriction Policies for Hepatitis C Treatment

NW Furukawa, SZ Ingber, H Symum… - JAMA Network …, 2024 - jamanetwork.com
Importance Hepatitis C can be cured with direct-acting antivirals (DAAs), but Medicaid
programs have implemented fibrosis, sobriety, and prescriber restrictions to control costs …

[HTML][HTML] An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank …

R Khalil, K Al-Mahzoum, M Barakat, M Sallam - Pathogens, 2024 - mdpi.com
Direct-acting antivirals (DAAs) revolutionized the therapeutics of chronic hepatitis C. The
emergence and transmission of HCV variants with resistance-associated substitutions …

Viral hepatitis in persons living with HIV in the post-COVID era

V Soriano, V Moreno-Torres, C De Mendoza, OJ Corral… - 2023 - reunir.unir.net
Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and
causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly …

Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)

DK van Santen, A Stewart, JS Doyle… - International journal …, 2024 - academic.oup.com
• The International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC) is a
multinational consortium of longitudinal cohorts of people with HIV who are at risk of …